Book a Meeting

Non-Fucosylated Anti-Human TGF3 (XPA.42.089) Therapeutic Antibody (CAT#: BioBet-1728ZP) Datasheet

Target
TGF3
Isotype
IgG
Description
Non-Fucosylated Anti-Human TGF3 (XPA.42.089) is a glycosylation-modified therapeutic biobetter antibody.
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced TGF3 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
TGFB3
Full Name
Transforming growth factor beta-3
Background
Transforming growth factor beta-3 is a protein that in humans is encoded by the TGFB3 gene.

It is a type of protein, known as a cytokine, which is involved in cell differentiation, embryogenesis and development. It belongs to a large family of cytokines called the Transforming growth factor beta superfamily, which includes the TGF-β family, Bone morphogenetic proteins (BMPs), growth and differentiation factors (GDFs), inhibins and activins.
Alternative Names
TGFB3, ARVD, ARVD1, RNHF, TGF-beta3, Transforming growth factor, beta 3, LDS5, transforming growth factor beta 3, TGF beta 3
Gene ID
Human: 7043; Mouse: 21809
UniProt ID
Human: P10600; Mouse: P17125
Genecards
TGFB3
Involvement in Disease
Diseases associated with TGFB3 include Loeys-Dietz Syndrome 5 and Arrhythmogenic Right Ventricular Dysplasia, Familial, 1. Among its related pathways are Degradation of the extracellular matrix and NF-KappaB Family Pathway.
Function
It is believed that TGF-β3 regulates molecules involved in cell adhesion and extracellular matrix (ECM) formation during the development of the upper jaw. Without TGF-β3, mammals will develop known cleft malformations. [8] [9] This is due to the failure of the fusion of epithelial cells on both sides of the imaging pa. TGF-β3 also plays a vital role in the control of mammalian lung development by regulating cell adhesion and ECM formation in this tissue [10], and by regulating the movement of epidermal and dermal cells in injured skin. Control wound healing. [5]
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
XPA.42.089
Host
Humanized
Species Reactivity
Human
Description
This clone was generated using a stable CHO cell line with the FUT8 knockout gene. It was 100% non-fucosylated. In an in vitro cell-based ADCC assay, the afucosylated antibody clone showed significantly higher ADCC activity compared to its wild type version. The binding affinity of the non-fucosylated Fc variant antibody to Fc receptor is much higher than than the same antibody with fucosylated Fc. Robust and stable production of qualitative fully non-fucosylated therapeutic antibodies is achieved.

Related Products

Non-Fucosylated Anti-Human TGF3 (XPA.42.068) Therapeutic Antibody (CAT#: BioBet-1729ZP)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.